seen from United States
seen from United States
seen from United States
seen from Poland
seen from Canada
seen from United States
seen from Ukraine
seen from Sweden
seen from Netherlands
seen from Türkiye
seen from Sweden
seen from T1
seen from Türkiye
seen from United States
seen from Malaysia
seen from Canada
seen from Netherlands
seen from United States
seen from Malaysia
seen from France
『SGMO_50周年夏祭り』無事に大盛況に終わりました♪ AIBO体験コーナー🐶や 光るおもちゃ夜店も完売し、豪華ソニー商品抽選会もありました🎁✨ 手筒花火もキレイでした✨🎆 ご近所のみなさま、ご来場のみなさまに喜んでいただけるように、また日々のお仕事がんばりたいと思います！ また来年もよろしくお願いいたします(^-^)/ #SGMO #AIBO #夏祭り #夜店 #Farmers https://www.instagram.com/p/B0qiXDMDjFd/?igshid=1f3uwzr5wy78c
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
『SGMO夏祭り🎆✨🐶』 2019/08/03(金) 今年で50周年の夏祭りを開催します！ 社外のみなさまも無料で参加でき、屋台、芸人漫才、手筒花火などがあり、感謝祭として、豪華ソニー商品の抽選プレゼントもあります🎁✨ 自分は、あのAIBO(アイボ)の無料体験会と光るおもちゃ店を開催しています🐶✨🌈 17:30から開催していますので、お気軽にお越しくださいませ(^-^)/ #SGMO #AIBO #夏祭り https://www.instagram.com/p/B0oUTB0DmHC/?igshid=nobmdiawhqlm
Volatile Trading With A Spread Of 21%, Sangamo Therapeutics Inc (Nasdaq:SGMO) Close At $13.05
Volatile Trading With A Spread Of 21%, Sangamo Therapeutics Inc (Nasdaq:SGMO) Close At $13.05
Sangamo Therapeutics Inc (Nasdaq:SGMO)
September 6th, 2018
Sangamo Therapeutics Inc fell $1.50 Saturday, a 10.31% decline, closing at $13.05. Sangamo Therapeutics Inc bounced 20.63% between low and high. Despite the drop in value, trading volumes were solid at 273% of normal which can indicate investor opportunities. (more…)
View On WordPress
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) has grabbed attention from the analysts, when it experienced a change of 9.49% in Monday’s afternoon trading session to trade at $16.42. A total of 1,506,15…
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM5.03 Amendment to Articles of Incorporation or Bylaws; Changes in Fiscal Year On January5, 2017, Sangamo BioSciences, Inc. (the Company) changed its corporate name to Sangamo Therapeutics, Inc. by filing the Third Certificate of Amendment of the Companys Seventh…
View On WordPress
Anya is live and ready to show you everything. Watch her strip, dance, and perform exclusive shows just for you. Interact in real-time and make your fantasies come true.
Free to watch • No registration required • HD streaming
Random Stock of the Week: SGMO
Sangamo BioSciences (SGMO) is a clinical stage biotech. Its pipeline is based on zinc finger nuclease and zinc finger transcription factors - ZFP TF. The most advanced clinical study is a phase 2b for a ZFP TF DNA plasmid, SB-509, which up-regulates the gene for vascular endothelial growth factor (VEGF)–A. SGMO is exploring a number of indications for SB-509, however the lead indication is for the treatment of diabetic neuropathy or DN.
So far results from the ZFP TF clinical experience have been relatively positive. A previous Ph2 clinical trial failed to meet an endpoint but the company dug into the data and identified a subset of patients that the drug appears to work in. Those patients suffer from moderate to severe DN; patients with mild DN were not eligible for the current Ph2b trial. Results from this trial are expected later this year - possibly as soon as August.
The Ph2b trial is randomized, double-blind, and placebo-controlled, with a number of "approvable" endpoints. So if this trial is successful, the company should have no problem designing their Ph3 with a likely path towards approval. Positive results from this trial may also yield a partner for the SB-509 program. The trial would also likely further validate the company's TF technology, resulting in partners for the company's plasmid technology in general or in other indications (the company has a broad IP portfolio including claims that cover other (e.g. ex-DN) indications and uses of the technology - SGMO already has some partnerships for non-therapeutic use.
Technically, the stock suffered since the issuance of new stock in April, just after the release of the latest 10K. Although a regulatory approval decision is likely a few years away, with a market cap of around $300Mio and with $80Mio in cash, given the potential of the ZFP (any successful drug would likely be a blockbuster - DN is an unmet medical need), and considering the upcoming first results of the phase 2b, there may be a bold move here.
